Skip to content
Sign in
SWC 2026 FinalistGrand Final: Lunch Block

Arelis

Melbourne start-up developing an at-home urine test with machine learning to screen for endometriosis.

Melbourne, Australia, OceaniaHealthTech, Women's health diagnostics (endometriosis)Australia – Melbourne regional (14 May 2026)
Stage
UndeterminedAI at the core
Product
R&DNone known
Funding raised
Undisclosedno funding
Founded
—
Founders
1Tori
Global score
3.5Grade DRank 111 of 151

Overview

Arelis Pty Ltd is developing a range of women's health tests, starting with endometriosis screening from a simple urine sample that can be collected at home. Founded by Tori Fox.

Traction

None known

No public evidence of traction found (urine endometriosis test in development, no published clinical study identified).

Market

Endometriosis diagnostics

Endometriosis affects a large share of women of reproductive age, yet diagnosis typically requires laparoscopy and takes years. A non-invasive screen would be bought first by gynaecologists and women's-health clinics to triage referrals, then by payers if it reduces diagnostic delay and surgery. Diagnostics are a regulated, evidence-driven market: clinical validation and reimbursement drive adoption. FemTech channels (pharmacies, telehealth, prescribing platforms) are emerging for at-home kits.

Addressable market

2025
$2.8B
2030
$4.1B
+7.8% a year

Endometriosis diagnostics: $2.8bn in 2025, $5.3bn in 2034 (CAGR 7.8%, Market Intelo).

Customers

Women with suspected endometriosis; gynaecology and women's-health clinics; telehealth providers

Who signs the cheque

Clinicians ordering tests, payers/insurers, and consumers for at-home kits

Geographies

  • Australia

Drivers

  • Long diagnostic delays and invasive gold standard
  • FemTech investment and awareness
  • At-home sample collection acceptance

Headwinds

  • No published clinical data
  • Regulatory approval required for a diagnostic
  • Unknown funding

Market Intelo estimates endometriosis diagnostics at $2.8bn in 2025 and $5.3bn in 2034 (CAGR 7.8%); non-invasive molecular diagnostics alone ~$0.54bn; 2030 extrapolated ~$4.1bn.

Scalability 5/10. Simple urine test that could be widely distributed, but requires clinical validation and diagnostic approvals country by country.

Market source: marketintelo.com

Technology

Category

In-vitro diagnostic with machine learning

AI at the coreMachine learning / predictive

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

R&D

How it works

A urine sample collected at home is analysed and machine-learning models build an endometriosis risk profile. No clinical study has been identified yet.

Moat

Potentially strong if biomarker signature and clinical dataset are proprietary; currently unproven.

Differentiation

Non-invasive and home-based versus imaging or surgical diagnosis.

Integration points

  • Telehealth and women's-health platforms
  • Pharmacy kit distribution
  • Clinical data networks for validation

Depends on

  • Clinical validation cohort
  • Regulatory clearance (TGA and others)
  • Lab analysis partner

Use of AI

Machine learning on a urine sample to build an endometriosis risk profile.

Product in detail

Machine learning/AI analysis of a urine sample to build an endometriosis risk profile.

Business

Model
Not disclosed; likely per-test sale to consumers or clinics.
Revenue logic
Per-test pricing (not published).
Go-to-market
Unknown; women's-health clinics and at-home channels are the logical routes.

Next milestones

  1. First clinical validation results
  2. Regulatory submission plan
  3. Seed round

Key risks

  • No clinical data
  • Regulatory pathway
  • Funding unknown

Opportunities

4 found in the network

Concrete moves for Arelis inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Distribution 2
  • Co-development 1
  • Investors 1

Distribution2

A channel or customer base to reach together

Use Hormony’s pharmacy kit channel for at-home women’s-health tests

Hormony already sells an at-home hormone kit through the Mannings pharmacy chain, proving a retail route for FemTech kits. Once validated, Arelis' test could follow the same channel and Hormony could broaden its shelf to a second women's-health indication.

20%confidence

Evidence from the records

  • “women's health tests, starting with endometriosis screening from a simple urine sample that can be collected at home”
  • “Kit sold in Hong Kong through the Mannings pharmacy chain.”
If it works
A pre-agreed distribution path for launch, strengthening the seed pitch.
First step
Schedule a founder call with Hormony to learn the pharmacy listing process and terms.

Route screening through IKI’s women’s-health prescribers

IKI equips clinicians who prescribe personalised programmes, notably for menopause; the same prescribers see endometriosis patients. Adding Arelis' screen as an orderable test in IKI would give Arelis a European clinician channel and IKI a diagnostic entry point.

15%confidence

Evidence from the records

  • “notably for menopause”
  • “Professional subscriptions on sale on the website”
  • “Machine learning/AI analysis of a urine sample to build an endometriosis risk profile.”
If it works
A clinician-facing pilot in Spain after validation.
First step
Share a product brief with IKI Health and ask for 3 gynaecologist advisers among its users.

Co-development1

An integration or joint product

Source de-identified clinical data to train and validate the model

Arelis' main gap is clinical data; Cromodata runs a de-identified clinical-data marketplace across dozens of hospitals in five countries. A data partnership could accelerate model development and external validation, and give Cromodata a FemTech data buyer.

20%confidence

Evidence from the records

  • “No clinical data”
  • “Pipeline for de-identifying and standardizing fragmented clinical records”
  • “claimed network of 47 to 84+ healthcare facilities in 5 countries”
If it works
A retrospective validation dataset at lower cost than a de-novo study.
First step
Ask Cromodata whether its network holds gynaecology/endometriosis-coded records and the access price.

Investors1

A fund whose thesis fits

Join StartUp Health’s global pre-seed health portfolio

StartUp Health invests at pre-seed/seed in HealthTech globally and co-led network member Wink Biotherapeutics' pre-seed, offering a warm introduction. Its long-term ‘health moonshot’ format suits an R&D-stage diagnostic.

25%confidence

Evidence from the records

  • “StartUp Health, Dreamward Ventures”
  • “Too early to invest.”
If it works
Pre-seed capital and access to a health-founder community.
First step
Request an intro to StartUp Health from Wink Biotherapeutics' founders.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

New York health-innovation company (since 2011) backing 500+ health founders in Moonshot communities: diagnostics, treatments, type 1 diabetes, Alzheimer's.

At-home urine test for endometriosis: women's-health diagnostics at R&D stage.

40%confidence

Evidence from the records

  • “Women's health diagnostics (endometriosis)”
  • “endometriosis screening from a simple urine sample”
First step
Apply once clinical validation data exist.

bioMérieux, French in-vitro diagnostics group, investing in MedTech and life sciences, including its Allergen Alert intrapreneurship spin-off.

Urine-based endometriosis diagnostic in development: in-vitro diagnostics in an underserved indication. R&D stage with no published clinical study, so a partnership-first approach fits.

40%confidence

Evidence from the records

  • “Women's health diagnostics (endometriosis)”
  • “urine endometriosis test in development”
Intro path
Allergen Alert (bioMérieux spin-off, network peer)
First step
Share the assay validation plan with bioMérieux corporate development.

Sydney early-stage VC backing Australian and New Zealand founders from idea to global scale (Canva, Linktree, ProcurePro).

Australian endometriosis diagnostics with AI at the core: a large underserved women's health market. No published clinical study, so it is too early for most AirTree cheques.

25%confidence

Evidence from the records

  • “Women's health diagnostics (endometriosis)”
  • “Australia”
First step
Return after first clinical validation data.

Investor with no profile in our data; invested an undisclosed amount in Spanish femtech/preventive health startup IKI Health.

Australian endometriosis diagnostics — women's health.

25%confidence

Evidence from the records

  • “IKI Health”
  • “Women's health diagnostics (endometriosis)”
  • “No public evidence of traction found (urine endometriosis test in development, no published clinical study identified).”
Intro path
Founder-to-founder intro via IKI Health (network portfolio company of Max Ventures).
First step
Qualify via IKI Health.

Australian VC with almost no public profile in our data; its only known deal is ProcurePro's 2026 Series B.

Australian women's health diagnostics — geography fits; no evidence Glitch invests in health.

20%confidence

Evidence from the records

  • “Australia”
  • “Women's health diagnostics (endometriosis)”
  • “No public evidence of traction found (urine endometriosis test in development, no published clinical study identified).”
Intro path
Founder-to-founder intro via ProcurePro (network portfolio company of Glitch Capital).
First step
Low priority: include in a batch outreach only.

Auckland early-stage VC backing Kiwi founders from pre-seed to growth as they build global companies from New Zealand.

Australian endometriosis diagnostics — Oceania; NZ link unknown.

20%confidence

Evidence from the records

  • “Oceania”
  • “Women's health diagnostics (endometriosis)”
  • “No public evidence of traction found (urine endometriosis test in development, no published clinical study identified).”
Intro path
Founder-to-founder intro via NEOCRETE (network portfolio company of Icehouse Ventures).
First step
Check NZ founder link first.

Investment analysis

3.5D

Grade D

Rank 111 of 151

Disruption7.0/10
Business model1.0/10
Market4.0/10
Risk(lower is better)9.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Too early to invest.

Disruption

7/10

At-home urine screening for endometriosis: a potentially transformative approach.

Business model

1/10

No traction, no published clinical study.

Market

4/10

Score 4/10: TAM $2.8bn → base 4; scalability 5/10 (0); no commercial presence in ≥2 countries yet (0).

Risk

9/10

Lower is better

Very high risk: no clinical or regulatory validation.

Strengths

  • Major medical need
  • Non-invasive approach

Risks

  • No clinical data
  • Unknown funding

Funding

Undisclosed, no funding
  1. 2026

    award (Startup World Cup Australia regional final, Melbourne; flights provided by United Airlines)not disclosed

    Startup World Cup Australia

Amount used in the study. No funding round; prize amount not disclosed.

Note. no public funding round found

verified, nothing to correct: Arelis Pty Ltd, tests in development (urine sample, AI), no clinical study or funding round published.

Team

  • Tori Fox

    Founder

    Melbourne-based founder of Arelis, a urine-sample endometriosis screening test.

Sources

Regional final
Australia – Melbourne regional (14 May 2026)
Identification confidence
high
  1. 1startupdaily.net/?p=137034
  2. 2arelis.ai/

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet